Evaluation of Quality of Life After Facial Hyaluroic Acid Injections Following Treatment for Brea… (NCT07425548) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Evaluation of Quality of Life After Facial Hyaluroic Acid Injections Following Treatment for Breast Cancer.
22 participantsStarted 2026-04
Plain-language summary
Breast cancer, the most common cancer in women, is increasingly managed as a chronic disease thanks to therapeutic advances. However, treatments such as chemotherapy and hormonotherapy often induce premature menopause in younger women, leading to skin aging, atrophy, and distressing symptoms that negatively affect quality of life. These cutaneous effects are frequently overlooked despite their psychological and social impact. Hyaluronic acid injections, already well established in aesthetic and reconstructive medicine, may offer a safe, minimally invasive option to restore skin quality, improve self-esteem, and enhance overall well-being in breast cancer survivors. This study aims to assess their efficacy and safety in this specific population.
Who can participate
Age range18 Years – 50 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Women ≥ 18 years old and ≤ 50 years old.
✓. Non-menopausal status at time of diagnosis of breast cancer (self-reporting).
✓. Patient with breast cancer (uni or bilateral):
✓. who completed their treatment at least 6 months ago including end of treatment with Herceptin but with the exception for ongoing hormone therapy
✓. in complete remission
✓. Non-immunosuppressed patient.
✓. Voluntarily signed and dated written informed consent prior to any study specific procedure.
Exclusion criteria
✕. Patients with a history of or declared autoimmune disease or immune system deficiency or undergoing immunosuppressive treatment. A 6-month washout is required.
What they're measuring
1
Facial appearance following facial hyaluronic acid injection following breast cancer treatment.
Timeframe: 3 months
2
Health-related quality of life followig facial hyaluronic acid injection following breast cancer treatment.
Timeframe: 3 months
3
Adverse effects following facial hyaluronic acid injection following breast cancer treatment.
✕. Patients undergoing or planning to undergo peeling treatment or laser/ultrasound-based or botox treatment or hyaluronic acid injections during the study or having had one of these treatments in the 6 months preceding the study.
✕. Patients showing cutaneous disorders, inflammation or infection (acne, herpes labialis, scars…) at the treatment site or near to this site.
✕. Patients having a known hypersensibility to lidocaine and/or amide local anaesthetic agents or hyaluronic acid and/or proteins from gram-positive bacteria, or with a history of severe allergy or anaphylactic shock.
✕. Patients with a history of streptococcal disease (recurrent sore throat, rheumatic fever)
✕. Patients with autoimmune or cardiac diseases (i.e. heart conduction disorders) and/or undergoing treatment for heart diseases (beta-blockers).
✕. Patients with hepatocellular insufficiency and/or undergoing treatment for liver disease.
✕. Patients suffering from epilepsy not controlled by a treatment or porphyria.